Secukinumab does not show greater clinical efficacy than placebo in patients with moderate-to-severe Graves' orbitopathy, ...

While argenx has been able to demonstrate the merit of its FcRn drug Vyvgart in multiple autoimmune indications, not every ...

“TED is 5 times more prevalent in women, and because of that, men are often overlooked for the diagnosis,” Nijm said. The ...

AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to ...

Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility review, while analysts maintain confidence in Vyvgart's broader growth.

The decision comes after the committee recommended halting the studies for futility after reviewing interim data.

The quickly-binding biologic lonigutamab demonstrated initial success in improving signs and symptoms of thyroid eye disease ...

Background/Aims To investigate immune-related ophthalmic side effects of systemic checkpoint inhibitors and compare side effect frequency and requirement for cessation of immunotherapy by checkpoint ...

I am a 68-year-old female who was first diagnosed with osteopenia and now osteoporosis. My physician has highly recommended ...